Medical technology company MGC Diagnostics has secured the US Food and Drug Administration (FDA) 510(k) clearance for its Resmon PRO FULL, Forced Oscillation Technique (FOT) device.
The device enables US healthcare professionals to non-invasively monitor a patient’s lung mechanics and normal breathing pattern, eliminating the need of forced efforts with traditional measurements.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Resmon PRO FULL is suited for use for elderly patients as well as children aged four and above.
MGC Diagnostics CEO Todd Austin said: “The Resmon PRO FULL is designed to provide medical professionals the ability to measure mechanical properties of the respiratory system during normal tidal breathing, providing a simple, effort-independent assessment for both clinicians and patients.”
Developed by Restech Respiratory Technology, the FOT features low dead space circuit which is aligned to anxiety tension state (ATS) and erythrocyte sedimentation rate (ERS) standards.
It supplements spirometry with information on mechanical properties of the respiratory system that otherwise may not be accessible via the conventional pulmonary function tests.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe device is suitable for critically ill patients as it requires less patient movement during the process.
The existing spirometry maneuver can hinder the effectiveness of a bronchodilator while the tidal breathing manuever of FOT has the ability to pronounce the effectiveness of a bronchodilator.
